VII. Uterussarkome

REFERENZEN

Abeler V. et al.: Uterine sarcomas in Norway. A histopathological and prognostic survey of a total population from 1970–2000 including 419 patients. Histopathology 2009; 54: 355–364

Abeler V. et al.: Diagnostic immunohistochemistry in uterine sarcomas: a study of 397 cases. Int J Gynecol Pathol 2011; 30 (3): 236–243

Abu-Rustum N.R. et al.: Regression of uterine low-grade smooth-muscle tumors metastatic to the lung after oophorectomy. Obstet Gynecol 1997; 89: 850–852

Berchuck A. et al.: Treatment of uterine leiomyosarcoma. Obstet Gynecol 1988; 71: 845–50

Berchuck A. et al.: Treatment of endometrial stromal tumors. Gynecol Oncol 1990; 36: 60–65

Bodner K. et al.: Prognostic parameters in endometrial stromal sarcoma: a clinicopathologic study in 31 patients. Gynecol Oncol 2001; 81: 160–165

Brooks S.E. et al.: Surveillance, epidemiology, and end results analysis of 2677 cases of uterine sarcoma 1989–1999. Gynecol Oncol 2004; 93: 204–208

Burns B. et al.: Morphologic features of prognostic significance in uterine smooth muscle tumors: a review of eighty-four cases. Am J Obstet Gynecol 1979; 135: 109–114

Chan J.K. et al.: Endometrial stromal sarcoma: a population-based analysis. Br J Cancer 2008; 99: 1210–1215

Chang K.L. et al.: Primary uterine endometrial stromal neoplasms. A clfinicopathologic study of 117 cases. Am J Surg Pathol 1990; 14: 415–438

D’Angelo E., Prat J.: Uterine sarcomas: a review. Gynecol Oncol 2010; 116 (1): 131–139

Demetri G.D. et al.: Efficacy and safety of trabectedin in patients with advanced and metastastic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol 2009; 27: 4188–4196

Ducimetière F. et al.: Incidence of sarcoma histotypes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testing. PLoS One 2011; 6 (8): e20294

Evans H.L. et al.: Smooth muscle neoplasms of the uterus other than ordinary leiomyoma. A study of 46 cases, with emphasis on diagnostic criteria and prognostic factors. Cancer 1988; 62: 2239–2247

FIGO committee on Gynecologic Oncology. FIGO staging for uterine sarcomas. Int J Gynecol Obstet 2009; 104: 179

Gadducci A. et al.: Endometrial stromal sarcoma: analysis of treatment failures and survival. Gynecol Oncol 1996; 63: 247–253

Gadducci A. et al.: The management of patients with uterine sarcoma: a debated clinical challenge. Crit Rev Oncol Hematol 2008; 65: 129–142

Garg G. et al.: Stage IA vs. IB endometrial stromal sarcoma: does the new staging system predict survival? Gynecol Oncol 2010; 118: 8–13

Giuntoli R.L. 2nd et al.: Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapy. Gynecol Oncol 2003; 89: 460–469

Goff B.A. et al.: Uterine leiomyosarcoma and endometrial stromal sarcoma: lymph node metastases and sites of recurrence. Gynecol Oncol 1993; 50 (1): 105–109

Hardman M.P. et al.: Metastatic uterine leiomyosarcoma regression using an aromatase inhibitor. Obstet Gynecol 2007; 110: 518–520

Hensley M.L. et al.: Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol 2002; 20: 2824–2831

Hensley M.L. et al.: Adjuvant gemcitabine plus docetaxel for completely resected stages I–IV high grade uterine leiomyosarcoma: Results of a prospective study. Gynecol Oncol 2009; 112 (3): 563–7

Hensley M.L. et al.: Adjuvant therapy for high-grade, uterus-limited leiomyosarcoma: results of a phase 2 trial (SARC 005). Cancer 2013; 119 (8): 1555–61

Jones M.W. et al.: Clinicopathologic study of 28 uterine leiomyosarcomas with metastasis. Int J Gynecol Pathol 1995; 14: 243–249

Kurihara S. et al.: Endometrial stromal sarcomas and related high-grade sarcomas: immunohistochemical and molecular genetic study of 31 cases. Am J Surg Pathol 2008; 32: 1228–38

Leath C.A. 3rd et al.: A multi-institutional review of outcomes of endometrial stromal sarcoma. Gynecol Oncol 2007; 105: 630–634

Leitao M.M. et al.: Incidence of lymph node and ovarian metastases in leiomyosarcoma of the uterus. Gynecol Oncol 2003; 91: 209–212

Lee C.H. et al.: 14–3–3 fusion oncogene in high-grade endometrial stromal sarcoma. Proc natl Acad Sci USA 2012; 109: 929–934

Leitao M.M. et al.: Tissue microarray immunohistochemical expression of estrogen, progesterone, and androgen receptors in uterine leiomyomata and leiomyosarcoma. Cancer 2004; 101: 1455–1462

Leunen M. et al.: Low-grade endometrial stromal sarcoma treated with the aromatase inhibitor letrozole. Gynecol Oncol 2004; 95: 769–771

Li N. et al.: Treatment options in stage I endometrial stromal sarcoma: A retrospective analysis of 53 cases. Gynecol Oncol 2008; 108: 306–311

Lissoni A. et al.: Conservative management of endometrial stroll sarcoma in young women. Int J Gynecol Cancer 1997; 7: 364–367

Major F.J. et al.: Prognostic factors in early-stage uterine sarcoma. A Gynecologic Oncology Group study. Cancer 1993; 71: 1702–1709

Malouf G.G. et al.: Impact of adjuvant treatment modalities on the management of patients with stages I–II endometrial stromal sarcoma. Ann Oncol 2010; 21: 2102–2106

Martin-Broto J. et al.: Randomized phase II study of trabectedin and doxorubicin compared with doxorubicin alone in first-line treatment in patients with advanced soft-tissue sarcomas: A Spanish group for research on sarcoma study. J Clin Oncol 2016; 34: 2294–2302

Muss H.B. et al.: Treatment of recurrent or advanced uterine sarcoma: a randomized trial of doxorubicin versus doxorubicin and cyclophosphamide: a phase III trial of the Gynecologic Oncology Group. Cancer 1985; 55: 1648–1653

Nordal R.N. et al.: Leiomyosarcoma and endometrial stroll sarcoma of the uterus. A survey of patients treated in the Norwegian Radium Hospital 1976–1985. Int J Gynecol Cancer 1993; 3: 110–115

Okuno S. et al.: Phase II trial of gemcitabine in advanced sarcomas. Cancer 2002; 94: 3225–3229

Omura G.A. et al.: A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a Gynecologic Oncology Group study. J Clin Oncol 1985; 3: 1240–1245

Omura G.A. et al.: A randomized study of adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas. Cancer 1983; 52: 626–632

Parker W.H. et al.: Uterine sarcoma in patients operated on for presumed leiomyoma and rapidly growing leiomyoma. Obstet Gynecol 1994; 83: 414–418

Pautier P. et al.: A randomized clinical trial of adjuvant chemotherapy with doxorubicin, ifosfamide, and cisplatin followed by radiotherapy versus radiotherapy alone in patients with localized uterine sarcomas (SARCGYN study). A study of the French Sarcoma Group. Ann Oncol 2013; 24 (4): 1099–104

Pautier P. et al.: Analysis of clinicopathologic prognostic factors for 157 uterine sarcomas and evaluation of a grading score validated for soft tissue sarcoma. Cancer 2000; 88: 1425–1431

Peters W.A. 3rd et al.: Uterine smooth-muscle tumors of uncertain malignant potential. Obstet Gynecol 1994; 83: 1015–1020

Petru E. et al.: Gynecologic Cancer Intergroup (GCIG) proposals for changes of the current FIGO staging system. Eur J Obstet Gynecol Retrod Biol 2009; 143: 69–74

Reed N.S. et al.: Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874). Eur J Cancer 2008; 44: 808–18

Reed N.S. et al.: Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an EORTC Gynaecological Cancer Group study (protocol 55874). Eur J Cancer 2008; 44: 808–818

Reich O., Regauer S. et al.: Expression of oestrogen and progesterone receptors in low-grade endometrial stromal sarcomas. Br J Cancer 2000; 82: 1030–1034

Reich O., Regauer S. et al.: Hormonal therapy of endometrial stromal sarcoma. Curr Opin Oncol 2007; 19: 347–352

Riopel J. et al.: Lymph node metastases in low-grade endometrial stromal sarcoma. Gynecol Oncol 2005: 96: 402–406

Sanfilippo R. et al.: Trabectedin in advanced uterine leiomyosarcomas: A retrospective case series analysis from two reference centers. Gynecol Oncol 2011; 23 (3): 553–6

Sumi A. et al.: Assessment of MR imaging as a tool to differentiate between the major histological types of uterine sarcomas. Man Reson Med Sci 2015; 14 (4). 295–304

Sutton G. et al.: Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcomas of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol 1996a; 62: 226–229

Sutton G. et al.: Ifosfamide treatment of recurrent or metastatic endometrial stromal sarcomas previously unexposed to chemotherapy: a study of the Gynecologic Oncology Group. Obstet Gynecol 1996b; 87: 747–750

Sutton G. et al.: Phase II trial of ifosfamide and mesna in leiomyosarcoma of the uterus: a Gynecologic Oncology Group study. Am J Obstet Gynecol 1992; 166: 556–559

S2k-Leitlinie Uterussarkom, AWMF-Registernummer 015/074, August 2015; www.awmf.org/leitlinien/detail/ll/015-074.html

Tanner E.J. et al.: High grade undifferentiated uterine sarcoma: surgery, treatment, and survival outcomes. Gynecol Oncol 2012; 127: 27–31

Wade K. et al.: Uterine sarcoma: steroid receptors and response to hormonal therapy. Gynecol Oncol 1990; 39: 364–367

Weitmann H.D. et al.: Radiation therapy in the treatment of endometrial stromal sarcoma. Int J Radiat Oncol Biol Phys 2001; 49: 739–48